scholarly journals Cortical Vein Thrombosis after Infliximab Treatment for Crohn’s Disease

2021 ◽  
Vol 13 (1) ◽  
pp. 120-124
Author(s):  
Saeed Razmeh ◽  
Nafiseh Niknam ◽  
Negar Sadat Rabbani ◽  
Shekoofeh Nikoee ◽  
Fatemeh Vafa Pour ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Pulmonary Thromboembolism ◽  
Infliximab Treatment ◽  
Cortical Vein ◽  
Vein Thrombosis ◽  
First Case ◽  
Cortical Vein Thrombosis ◽  
Inflammatory Bowel ◽  
Deep Vein

Inflammatory bowel disease (IBD) including ulcerative colitis and Crohn’s disease puts patients at high risk of thromboembolism accidents. These patients may take infliximab for active and fistulating Crohn’s disease, which can also increase the risk of thrombosis. Deep vein thrombosis (DVT) and pulmonary thromboembolism (PTE) are more common among these patients, but cerebrovascular, mesenteric, portal and retinal veins can also be affected. In this paper, we report a case of isolated right Labbe vein thrombosis after infliximab therapy for Crohn’s disease. To the best of our knowledge, our patient is the first case report of isolated cortical vein thrombosis following administration of rituximab for Crohn’s disease.

scholarly journals Portal Vein Thrombosis and Systemic Amyloidosis in Crohn’s Disease: A Case Report and Review of the Literature

1996 ◽  
Vol 10 (5) ◽  
pp. 297-300 ◽  
Author(s):  
Gad Friedman ◽  
Gary E Wild
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Portal Vein ◽  
Portal Vein Thrombosis ◽  
Protein S ◽  
Systemic Amyloidosis ◽  
Vein Thrombosis ◽  
First Case ◽  
S Deficiency ◽  
Inflammatory Bowel

Systemic amyloidosis and portal vein thrombosis are relatively rare complications of inflammatory bowel disease. The first case of a patient with Crohn’s disease presenting with both complications is presented. An acquired free protein S deficiency was disclosed in the patient, which may be responsible for the hypercoagulable state observed in Crohn’s disease and the nephrotic syndrome from amyloidosis.

scholarly journals Crohn's Disease Initially Accompanied by Deep Vein Thrombosis and Ulnar Neuropathy without Metronidazole Exposure

Gut and Liver ◽  
2013 ◽  
Vol 7 (2) ◽  
pp. 252-254 ◽  
Author(s):  
Woohyeon Kim ◽  
Borami Kang ◽  
Byung-Wook Kim ◽  
Joon Sung Kim ◽  
Hae-Mi Lee ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Deep Vein Thrombosis ◽  
Crohn's Disease ◽  
Ulnar Neuropathy ◽  
Vein Thrombosis ◽  
Deep Vein

scholarly journals A study on the effectiveness of wells criteria for diagnosing deep vein thrombosis: a prospective observational study

2021 ◽  
Vol 8 (2) ◽  
pp. 569
Author(s):  
Dhanaraj Palanisamy ◽  
Akshay Omkumar
Keyword(s):  
Deep Vein Thrombosis ◽  
Single Case ◽  
Post Partum ◽  
Clinical Signs ◽  
Study Group ◽  
Cortical Vein ◽  
Vein Thrombosis ◽  
Cortical Vein Thrombosis ◽  
Wells Score ◽  
Deep Vein

Background: Wells score which takes into account various aspects in the history as well as various clinical signs which can help the clinician to arrive at a diagnosis of deep vein thrombosis (DVT). This helps to save time and money that is wasted in doing many unnecessary investigations. Aim of the study was to test the application of the Wells score in our clinical set up and to see how effectively we can diagnose DVT.Methods: This was a prospective diagnostic validation study of the wells rule for DVT in our setup, ultrasound (USG) being the gold standard comparison and will be conducted over a duration of 12 months. Wells score for each patient was calculated and the results were evaluated.Results: Among the 50 cases suspected DVT, the wells score was able to predict DVT in 46 of the cases thus proving to be a very efficient diagnostic indicator. The average wells score among the various cases was 4/8. Complications noted in the study group were 2 cases of cortical vein thrombosis in the post-partum period which fully recovered. Mortality rate in the study group was 4.3% in which a single case of diagnosed myocardial infarction died of heart failure.Conclusions: Wells score is indeed a very good predictive criteria for DVT and can be applied with ease as it required only clinical assessment and thus avoids unnecessary delays in waiting for scans thereby allowing us to start anticoagulants as early as possible.

Acquired pial arteriovenous fistula secondary to cerebral cortical vein thrombosis: A case report and review of the literature

2021 ◽  
pp. 197140092110490
Author(s):  
Skander Sammoud ◽  
Nadia Hammami ◽  
Dhaker Turki ◽  
Fatma Nabli ◽  
Samia Ben Sassi ◽  
...  
Keyword(s):  
Low Flow ◽  
Left Middle Cerebral Artery ◽  
Cerebral Vein ◽  
Cortical Vein ◽  
Arteriovenous Fistulas ◽  
Vein Thrombosis ◽  
Sagittal Sinus ◽  
Venous Circulation ◽  
First Case ◽  
Cortical Vein Thrombosis

Pial arteriovenous fistulas (AVFs) are rare neurovascular malformations. They differ from arteriovenous malformations (AVMs) in that they involve single or multiple feeding arteries, draining directly into a dilated cortical vein with no intervening nidus. Pial and dural AVFs differ in blood supply, as the first originate from pial or cortical arteries and the latter from outside the dural leaflets. Unlike dural AVFs, most of the pial AVFs are supratentorial. The vast majority are congenital, manifesting during infancy. Acquired pial AVFs are significantly rarer and occur after vasculopathy, head trauma, brain surgery, or cerebral vein thrombosis. We describe a unique case of an acquired pial AVF in a 50-year-old man secondary to a cortical vein thrombosis manifesting as a focal-onset seizure with secondary generalization. A cerebral digital subtraction angiography revealed a low-flow pial AVF fed by a postcentral branch of the left middle cerebral artery draining to the superior sagittal sinus via a cortical vein. It also showed a collateral venous circulation adjacent to the previously thrombosed left parietal vein. There was no evidence of an associated dural AVF or venous varix. Endovascular treatment was scheduled three months later, but the angiogram preceding the embolization showed spontaneous and complete closure of the malformation. To our knowledge, this is the first case illustrating acquired pure pial AVF unaccompanied by a dural component following cortical vein thrombosis, eventually resulting in an unprompted closure.

scholarly journals Deep Vein Thrombosis: A Rare Association with Tuberculosis.

2012 ◽  
Vol 13 (1) ◽  
pp. 106-108 ◽  
Author(s):  
Supriya Sarkar ◽  
Kaushik Saha ◽  
Malay Kumar Maikap ◽  
Debraj Jash
Keyword(s):  
Deep Vein Thrombosis ◽  
Pulmonary Thromboembolism ◽  
Young Male ◽  
Sputum Smear ◽  
Vein Thrombosis ◽  
Rare Association ◽  
First Case ◽  
Smear Positive Pulmonary Tuberculosis ◽  
Male Patients ◽  
Deep Vein

We are reporting two cases of bilateral extensive lower leg deep vein thrombosis in young male patients without any risk factors. First case was diagnosed as left sided tuberculous pleural effusion and second case was sputum smear positive pulmonary tuberculosis. In both patients, deep vein thrombosis developed during first month of treatment and inguinal pain was the first symptom. The second case had an attack of pulmonary thromboembolism. The cause effect relationship between deep vein thrombosis and tuberculosis or anti-tubercular drug (particularly rifampicin) has been discussed as such association may have significant therapeutic implications.DOI: http://dx.doi.org/10.3329/jom.v13i1.8843 JOM 2012; 13(1): 106-108

scholarly journals Hypercoagulability in ACTH-Dependent Cushing Syndrome

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A644-A645
Author(s):  
Amit Kartar Singh Sumal ◽  
Laurence Katznelson
Keyword(s):  
Venous Thromboembolism ◽  
Cushing Syndrome ◽  
Thrombotic Event ◽  
Curative Surgery ◽  
Cushing Disease ◽  
Cortical Vein ◽  
Vein Thrombosis ◽  
Cortical Vein Thrombosis ◽  
The Mean ◽  
Deep Vein

Abstract Introduction: ACTH-dependent Cushing syndrome (CS) is associated with hypercoagulability; however, the incidence and timing of thrombosis during evaluation and management of CS is unclear. Objective: To evaluate the incidence and timing of thrombotic events in patients with ACTH-dependent CS following diagnosis and management. Methods: We performed a retrospective, longitudinal study of patients with ACTH-dependent CS seen at Stanford University Health Care from 1998 to 2020. Thrombotic events — deep vein thrombosis (DVT), pulmonary embolism (PE), cerebral vascular accident (CVA), and myocardial infarction (MI) — were recorded between diagnosis and 12 months following therapeutic intervention. Results: Of 108 patients with ACTH-dependent CS, 97 (89.8%) were women, and the mean age at diagnosis was 43.0 years (± 15.7 years). Sixty-eight (63%) patients had hypertension, 38 (35.2%) had diabetes mellitus, and 11 (10.2%) were active smokers. Of the 108 subjects, 97 (89.8%) had Cushing Disease (CD) and 11 (10.2%) had ectopic CS. Of the 97 patients with CD, 38 (39.2%) underwent inferior petrosal sinus sampling (IPSS), 59 (60.8%) underwent transsphenoidal surgery (TSS), 19 required repeat TSS (19.6%), and 15 underwent TSS and bilateral adrenalectomy (BAL) (15.4%). Of the 11 patients with ectopic CS, 3 (27.2%) underwent IPSS, 6 (54.5%) underwent BAL, and 1 (9.1%) underwent TSS and BAL. There were 10 thrombotic events among 7 (7.2%) CD patients, but no thrombotic events among ectopic CS patients. Of the thrombotic events, there were 7 (70%) DVT/PE, 2 (20%) CVA, and 1 (10%) cortical vein thrombosis. Six (60%) occurred within 30 days after TSS (range 3-25 days), 2 (20%) between 31 days and 1 year after TSS (range 59-165 days), 1 (10%) 26 days after IPSS but prior to TSS, and 1 (10%) in a patient who did not undergo IPSS or surgery. No thrombotic events were noted after BAL. Of the 8 postoperative thrombotic events, 5 (62.5%) occurred while patients received supraphysiologic glucocorticoid replacement (defined as >25mg hydrocortisone or equivalent daily) after curative surgery, 1 (12.5%) occurred after a patient was tapered to physiologic glucocorticoid replacement, and 2 (25%) occurred in patients who had persistent disease despite surgery. The degree of hypercortisolism at baseline was not associated with risk of thrombotic events. Conclusions: In this retrospective study, 6.5% of ACTH-dependent CS patients had a thrombotic event, all in patients with CD. The majority had venous thromboembolism with DVT/PE, and the highest incidence occurred up to 30 days after surgery. The degree of hypercortisolism at baseline did not correlate with subsequent thrombotic events. Therefore, it is important to monitor all patients with ACTH-dependent CS following surgical intervention for venous thromboembolism.

scholarly journals Development of pulmonary sarcoidosis in Crohn’s disease patient under infliximab biosimilar treatment after long-term original infliximab treatment: a case report and literature review

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Shin Kashima ◽  
Kentaro Moriichi ◽  
Katsuyoshi Ando ◽  
Nobuhiro Ueno ◽  
Hiroki Tanabe ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Disease Patient ◽  
Skin Lesions ◽  
Pulmonary Sarcoidosis ◽  
Pathological Examination ◽  
Unknown Etiology ◽  
Infliximab Treatment ◽  
First Case ◽  
Case Presentations

Abstract Background Inflammatory bowel disease (IBD) is chronic inflammation of the gastrointestinal tract, although its etiology has largely been unclear. Tumor necrosis factor inhibitors (TNF-I) are effective for the treatment. Recently, biosimilars of TNF-I, such as CT-P13, have been developed and are thought to possess equal efficacy and safety to the original TNF-I. Sarcoidosis is also a systemic granulomatous disease of unknown etiology. In steroid-resistant cases of sarcoidosis, TNF-I have been reported effective for achieving resolution. However, the progression of sarcoidosis due to the TNF-I also has been reported. We herein report a case of pulmonary sarcoidosis with a Crohn’s disease (CD) patient developed after a long period administration (15 years) of TNF-I. Case presentations A 37-year-old woman with CD who had been diagnosed at 22 years old had been treated with the TNF-I (original infliximab; O-IFX and infliximab biosimilar; IFX-BS). Fifteen years after starting the TNF-I, she developed a fever and right chest pain. Chest computed tomography (CT) revealed clustered small nodules in both lungs and multiple enlarged hilar lymph nodes. Infectious diseases including tuberculosis were negative. Bronchoscopic examination was performed and the biopsy specimens were obtained. A pathological examination demonstrated noncaseating granulomatous lesions and no malignant findings. TNF-I were discontinued because of the possibility of TNF-I-related sarcoidosis. After having discontinued for four months, her symptoms and the lesions had disappeared completely. Fortunately, despite the discontinuation of TNF-I, she has maintained remission. Conclusions To our knowledge, this is the first case in which sarcoidosis developed after switching from O-IFX to IFX-BS. To clarify the characteristics of the cases with development of sarcoidosis during administration of TNF-I, we searched PubMed and identified 106 cases. When developing an unexplained fever, asthenia, uveitis and skin lesions in patients with TNF-I treatment, sarcoidosis should be suspected. Once the diagnosis of sarcoidosis due to TNF-I was made, the discontinuation of TNF-I and administration of steroid therapy should be executed promptly. When re-starting TNF-I, another TNF-I should be used for disease control. Clinicians should be aware of the possibility of sarcoidosis in patients under anti-TNF therapy.

scholarly journals COVID-19 and thrombosis

2021 ◽  
Vol 8 (10) ◽  
pp. 5154
Author(s):  
Kavita Verma ◽  
Anjali Sharma ◽  
Shahzad Sarosh Bulsara
Keyword(s):  
Pulmonary Thromboembolism ◽  
Fungal Infections ◽  
Virus Disease ◽  
Kidney Injury ◽  
Limb Ischemia ◽  
Vein Thrombosis ◽  
First Case ◽  
Liver And Kidney ◽  
Arterial Thromboembolic Events ◽  
Deep Vein

The first case of novel corona virus disease (COVID-19) was reported in China and undoubtedly today this disease has rapidly crossed borders, infecting people throughout the world. There are heaps of complications related to COVID-19 namely acute respiratory failure, acute liver and kidney injury, bacterial and fungal infections, and septic shock. Vascular thrombosis is another burden that COVID-19 is pilling on to the load of its complications. Venous thromboembolism namely deep vein thrombosis and pulmonary thromboembolism; pulmonary microvasculature thrombosis and systemic arterial thromboembolic events like limb ischemia, myocardial ischemia/infarction and cerebrovascular thrombosis are being increasingly reported in COVID-19 patients.

Sign in / Sign up

Export Citation Format

Share Document